ERBB3 and ovarian cancer: For example, seribantumab (MM-121), a neutralizing mAb against ErbB3, significantly reduced tumor growth in xenograft models of lung and ovarian cancer derived from patients with carcinogenic neuregulin 1 (NRG1) fusion [22].